Drug treatments for obesity/Bibliography: Difference between revisions
Jump to navigation
Jump to search
imported>Rachael Kirkbride No edit summary |
imported>Rachael Kirkbride No edit summary |
||
Line 5: | Line 5: | ||
2. Coutinho W. (2009)The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ''Arquivos Brasileiros De Endocrinologia E Metabologia.'' 53:262-270 ''"The most | 2. Coutinho W. (2009)The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ''Arquivos Brasileiros De Endocrinologia E Metabologia.'' 53:262-270 ''"The most | ||
widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for | ''widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for | ||
about a decade."'' | about a decade."'' | ||
==Primary Research Papers== | ==Primary Research Papers== |
Revision as of 09:14, 6 October 2009
- Please sort and annotate in a user-friendly manner. For formatting, consider using automated reference wikification.
Review Articles
1. Magni P. et al. (2009) Feeding behavior in mammals including humans. Ann.N.Y.Acad.Sci. 1163:221-232. PMID 19456343
2. Coutinho W. (2009)The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos Brasileiros De Endocrinologia E Metabologia. 53:262-270 "The most widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for about a decade."